brivanib alaninate

Drug Overview

Brivanib alaninate is an experimental cancer medication. It belongs to a modern family of cancer treatments known as Targeted Therapies or “Smart Drugs.” Unlike older chemotherapy drugs that attack all fast-growing cells in the body, targeted therapies are designed to seek out and block specific signals that tumors use to survive and grow.

While brivanib showed early promise as a way to “starve” tumors by cutting off their blood supply, it did not pass its final stages of clinical testing. Therefore, it is not available at regular pharmacies and is primarily known through clinical research data.

• Generic Name: Brivanib alaninate
• US Brand Names: None (Investigational Agent)
• Drug Class: Dual VEGFR and FGFR Tyrosine Kinase Inhibitor (Targeted Therapy)
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Not FDA Approved. It is strictly an investigational drug used in clinical research and its main development has been halted.

What Is It and How Does It Work? (Mechanism of Action)

Brivanib alaninate is a Targeted Therapy designed to stop tumors from building their own blood vessels—a process called angiogenesis.

To grow larger than the size of a pinhead, a tumor needs its own blood supply to bring it oxygen and nutrients. To build this “plumbing system,” cancer cells release specific chemical signals into the body. These signals lock onto two main receptors on the surface of blood vessel cells:

1. VEGFR (Vascular Endothelial Growth Factor Receptor)
2. FGFR (Fibroblast Growth Factor Receptor)

At the molecular level, brivanib alaninate works by plugging into these specific VEGFR and FGFR receptors, acting like a roadblock. By blocking these receptors, the drug shuts down the signaling pathways inside the cell. Without these chemical signals, the body stops building new blood vessels for the tumor. Without a steady supply of blood, oxygen, and food, the cancer cells starve, stop dividing, and eventually die.

FDA Approved Clinical Indications

Because brivanib alaninate is an investigational drug that did not complete the final steps for commercial use, it does not have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

• Historically studied for the treatment of advanced Hepatocellular Carcinoma (HCC), which is the most common type of liver cancer.
• Studied in advanced colorectal cancer (colon cancer) and other solid tumors that have stopped responding to standard treatments.

Non-Oncological Uses

• There are no FDA-approved or investigational non-oncological uses for this drug.

Dosage and Administration Protocols

Because brivanib alaninate was strictly an investigational medicine, there is no single, commercially available prescription dosage. The dosing below reflects the protocols used during its major Phase 3 clinical trials (such as the BRISK trials) before its widespread development was paused.

• 
  Renal and Hepatic Insufficiency: Because the drug is processed heavily by the liver, patients with severe liver failure were usually excluded from trials. If a patient’s liver enzymes spiked during the trial, the research doctor would typically lower the dose to 400 mg or pause the medication completely to allow the liver to recover.

Clinical Efficacy and Research Results

Recent oncological reviews (spanning 2020-2026) frequently analyze the past clinical trial data of brivanib to understand how liver cancers become resistant to drugs. Brivanib underwent massive Phase 3 trials (known as BRISK-FL and BRISK-PS) for liver cancer.

• Survival Rates: In these major clinical trials for advanced liver cancer, patients taking brivanib had a median overall survival of approximately 9.4 to 9.5 months.
• Effects on Disease Progression: While the drug did show some ability to shrink tumors or keep them from growing for a few months (progression-free survival), it ultimately failed its main test.
• Current Status: The primary reason development was stopped was that brivanib did not prove to be significantly better at extending a patient’s life than the existing standard drugs (like sorafenib) or placebos used at the time. Therefore, it was not approved for general use.

Safety Profile and Side Effects

Like all drugs that block blood vessel growth, brivanib alaninate caused side effects related to blood pressure and digestion. Because it is not FDA-approved, it does not carry a formal “Black Box Warning,” but serious risks were monitored closely.

Common Side Effects (>10%)

• Hypertension: High blood pressure was one of the most common side effects.
• Fatigue: Severe tiredness and weakness.
• Gastrointestinal Upset: Diarrhea, decreased appetite, and nausea.
• Hand-Foot Syndrome: Redness, swelling, and pain on the palms of the hands and soles of the feet.

Serious Adverse Events

• Hepatotoxicity: Elevated liver enzymes, showing stress or damage to the liver.
• Hemorrhage (Bleeding): Because the drug affects blood vessels, there is a higher risk of severe bleeding in the stomach or intestines.
• Hyponatremia: Dangerously low sodium levels in the blood.

Management Strategies

• Doctors closely managed high blood pressure by prescribing standard blood pressure medications. If blood pressure remained too high, the brivanib dose was lowered.
• Patients with diarrhea were given over-the-counter anti-diarrheal medicines and instructed to drink lots of fluids to prevent dehydration.

Research Areas

While brivanib itself is not used in stem cell therapy, its dual-action design has helped shape current Regenerative Medicine and cancer research. Scientists have learned that “Cancer Stem Cells”—the deeply hidden, stubborn cells that cause cancer to return—often use the FGFR pathway to survive and hide from the immune system. By studying how brivanib blocked FGFR, today’s researchers are developing newer, safer targeted therapies and combining them with Immunotherapy. The goal is to break down the tumor’s defenses so the patient’s own immune system can permanently wipe out the cancer stem cells.

Patient Management and Practical Recommendations

(Note: Since brivanib is largely discontinued, these recommendations apply generally to patients participating in clinical trials for similar blood-vessel-blocking drugs).

Pre-Treatment Tests to be Performed

• Comprehensive Metabolic Panel (CMP): To deeply evaluate liver function (AST, ALT, bilirubin) before starting.
• Complete Blood Count (CBC): To check baseline blood health.
• Baseline Blood Pressure: To ensure the patient does not already have dangerous high blood pressure.

Precautions During Treatment

• Patients in these types of trials must have their blood pressure checked at home daily.
• Extreme care is needed to watch for signs of bleeding, as these drugs can weaken the walls of blood vessels.

Do’s and Don’ts

• DO report any unusual bruising, bleeding gums, dark “tarry” stools, or pink urine to your doctor immediately.
• DO keep a daily log of your blood pressure readings to share with your oncology team.
• DON’T take over-the-counter pain medicines like aspirin, ibuprofen (Advil/Motrin), or naproxen (Aleve) without asking your doctor, as these can thin the blood and greatly increase bleeding risks.
• DON’T ignore sudden dizziness or extreme fatigue, as this could be a sign of low sodium or liver stress.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Brivanib alaninate is an investigational product and is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.